All posts by IOM Topic: Quality and Patient Safety

Strategies to Improve Cardiac Arrest Survival: A Time to Act

The Institute of Medicine conducted a study on the current status of, and future opportunities to improve, cardiac arrest treatment and outcomes in the United States. This report examines the complete system of response to cardiac arrest in the United States and identifies opportunities within existing and new treatments, strategies, and research that promise to improve survival and recovery of patients. More

Transforming Health Care Scheduling and Access: Getting to Now

The Institute of Medicine (IOM) report Crossing the Quality Chasm identified six fundamental aims for health care—that it be safe, effective, patient-centered, efficient, equitable, and timely. Of these fundamental aims, timeliness is in some ways the least well studied and understood. How can timely care be ensured in various health care settings, and what are some of the reasons that care is sometimes not timely? The report presented here was developed by the IOM Committee on Optimizing Scheduling in Health Care to answer such questions. More

Sex Differences and Implications for Translational Neuroscience Research – Workshop Summary

Biological differences between the sexes influence not only individual health but also public health, biomedical research, and health care. The IOM held a workshop March 8-9, 2010, to discuss sex differences and their implications for translational neuroscience research, which bridges the gap between scientific discovery and application. More

Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa: Reducing the Treatment Gap, Increasing Quality of Care – Workshop Summary

Millions of people in sub-Saharan Africa suffer from mental, neurological, and substance use (MNS) disorders, and most do not have the resources to obtain treatment. The Uganda National Academy of Sciences and the IOM hosted a workshop to discuss the state of care for MNS disorders in sub-Saharan Africa. More

Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System – A Workshop

Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer’s, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The IOM’s Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. More

CNS Clinical Trials: Suicidality and Data Collection – Workshop Summary

The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior. The IOM’s Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future. More

From Molecules to Minds: Challenges for the 21st Century. Workshop Summary

On June 25, 2008, the IOM Forum on Neuroscience and Nervous System Disorders hosted more than 70 of the leading neuroscientists in the world, for a workshop titled From Molecules to Minds: Challenges for the 21st Century. The objective of the workshop was to explore a set of common goals or “Grand Challenges” posed by participants that could inspire and rally both the scientific community and the public to consider the possibilities for neuroscience in the 21st century. More